New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 21, 2014
09:42 EDTVRXValeant to sell Precision's assets related to two acne treatments
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Valeant Pharmaceuticals International's proposed $475M acquisition of Precision Dermatology. would likely be anticompetitive. Under the order, Valeant has agreed to sell Precision’s assets related to two acne treatments – Tretin-X, its branded single-agent topical tretinoin, and generic Retin-A – within 10 days of consummating the transaction. According to the FTC’s complaint, first announced in July, Valeant’s acquisition of Precision as originally proposed would likely reduce competition in the market for branded and generic single-agent topical tretinoins, and in a separate market for generic Retin-A. Reference Link
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
19:54 EDTVRXValeant to expand Canadian presence in coming years, Globe and Mail says
Subscribe for More Information
May 20, 2015
06:37 EDTVRXSources: Valeant in talks to buy Amoun Pharmaceutical, Bloomberg reports
Subscribe for More Information
06:32 EDTVRXValeant CEO sees quintupling in Asia sales by 2020, Reuters reports
Subscribe for More Information
May 15, 2015
17:15 EDTVRXPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:08 EDTVRXSoros Fund gives quarterly update on stakes
Subscribe for More Information
17:03 EDTVRXPershing Square gives quarterly update on stakes
Subscribe for More Information
10:55 EDTVRXJANA Partners gives quarterly update on stakes
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use